Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Journal
The Lancet Oncology
Journal Volume
19
Journal Issue
1
Pages
115-126
Date Issued
2018
Author(s)
Hurvitz S.A.
Martin M.
Symmans W.F.
Jung K.H.
Thompson A.M.
Harbeck N.
Valero V.
Stroyakovskiy D.
Wildiers H.
Campone M.
Boileau J.-F.
Beckmann M.W.
Afenjar K.
Fresco R.
Helms H.-J.
Xu J.
Lin Y.G.
Sparano J.
Slamon D.
Abstract
Background HER2-targeted treatments have improved outcomes in patients with HER2-positive breast cancer in the neoadjuvant, adjuvant, and metastatic settings; however, some patients remain at risk of relapse or death for many years after treatment of early-stage disease. Therefore, new strategies are needed. We did a phase 3 trial to assess a neoadjuvant regimen for HER2-positive breast cancer that replaces traditional systemic chemotherapy with targeted treatment. Methods We did a randomised, open-label phase 3 KRISTINE trial in 68 Translational Research In Oncology centres (hospitals and specialty cancer centres in Asia, Europe, USA, and Canada). Eligible participants were aged 18 years or older with centrally confirmed HER2-positive stage II–III operable breast cancer (>2 cm tumour size), an Eastern Cooperative Oncology Group performance status of 0–1, and a baseline left ventricular ejection fraction of at least 55% (by echocardiogram or multiple-gated acquisition scan). We randomly assigned participants (1:1) to receive either trastuzumab emtansine plus pertuzumab or docetaxel, carboplatin, and trastuzumab plus pertuzumab. We did the randomisation via an interactive response system under a permuted block randomisation scheme (block size of four), stratified by hormone receptor status, stage at diagnosis, and geographical location. Patients received six cycles (every 3 weeks) of neoadjuvant trastuzumab emtansine plus pertuzumab (trastuzumab emtansine 3·6 mg/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses) or docetaxel, carboplatin, and trastuzumab plus pertuzumab (docetaxel 75 mg/m2; carboplatin area under the concentration–time curve 6 mg/mL × min; trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance doses) plus pertuzumab [same dosing as in the other group]). All treatments were administered intravenously. The primary objective was to compare the number of patients who achieved a pathological complete response (ypT0/is, ypN0), between groups in the intention-to-treat population (two-sided assessment), based on local evaluation of tumour samples taken at breast cancer surgery done between 14 days and 6 weeks after completion of neoadjuvant therapy. Safety was analysed in patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, number NCT02131064, and follow-up of the adjuvant phase is ongoing. Findings Between June 25, 2014, and June 15, 2015, we randomly assigned 444 patients to neoadjuvant treatment with trastuzumab emtansine plus pertuzumab (n=223) or docetaxel, carboplatin, and trastuzumab plus pertuzumab (n=221). A pathological complete response was achieved by 99 (44·4%) of 223 patients in the trastuzumab emtansine plus pertuzumab group and 123 (55·7%) of 221 patients in the docetaxel, carboplatin, and trastuzumab plus pertuzumab group (absolute difference ?11·3 percentage points, 95% CI ?20·5 to ?2·0; p=0·016). During neoadjuvant treatment, compared with patients receiving docetaxel, carboplatin, and trastuzumab plus pertuzumab, fewer patients receiving trastuzumab emtansine plus pertuzumab had a grade 3–4 adverse event (29 [13%] of 223 vs 141 [64%] of 219) or a serious adverse event (11 [5%] of 223 vs 63 [29%] of 219). The most common grade 3–4 adverse events in the trastuzumab emtansine plus pertuzumab group were decreased platelet count (three [1%] of 223 patients vs 11 [5%] of 219 with docetaxel, carboplatin, and trastuzumab plus pertuzumab), fatigue (three [1%] vs seven [3%]), alanine aminotransferase increase (three [1%] vs four [2%]), and hypokalaemia (three [1%] vs five [2%]). The most common grade 3–4 adverse events in the docetaxel, carboplatin, and trastuzumab plus pertuzumab group were neutropenia (55 [25%] of 219 vs one [<1%] of 223 with trastuzumab emtansine plus pertuzumab), diarrhoea (33 [15%] vs 2 [<1%]), and febrile neutropenia (33 [15%] vs 0). No deaths were reported during neoadjuvant treatment. Interpretation Traditional neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade (docetaxel, carboplatin, and trastuzumab plus pertuzumab) resulted in significantly more patients achieving a pathological complete response than HER2-targeted chemotherapy plus HER2-targeted blockade (trastuzumab emtansine plus pertuzumab); however, numerically more grade 3–4 and serious adverse events occurred in the chemotherapy plus trastuzumab and pertuzumab group. Further efforts to improve the efficacy of chemotherapy without imparting more toxicity are warranted. Funding F Hoffmann-La Roche and Genentech. ? 2018 Elsevier Ltd
SDGs
Other Subjects
alanine aminotransferase; aspartate aminotransferase; carboplatin; docetaxel; gamma glutamyltransferase; pertuzumab; trastuzumab; trastuzumab emtansine; antineoplastic agent; carboplatin; docetaxel; epidermal growth factor receptor 2; ERBB2 protein, human; maytansine; monoclonal antibody; pertuzumab; taxoid; trastuzumab; trastuzumab emtansine; tumor marker; abdominal pain; acute kidney failure; adenomyosis; adult; alopecia; anaphylaxis; anemia; anxiety; Article; asthenia; backache; bacteremia; body weight loss; Clostridium difficile infection; colitis; constipation; controlled study; decreased appetite; deep vein thrombosis; dehydration; device infection; diarrhea; dizziness; drug dose reduction; drug response; dysesthesia; dysgeusia; dysuria; enterocolitis; epistaxis; erythema; faintness; fatigue; febrile neutropenia; fever; gastritis; gastroenteritis; gastrointestinal hemorrhage; headache; hematoma; human; human epidermal growth factor receptor 2 positive breast cancer; hypermagnesemia; hypersensitivity; hypertension; hypertensive crisis; hypertransaminasemia; hypoalbuminemia; hypokalemia; hypomagnesemia; infectious diarrhea; intestine perforation; kidney infection; leukocyte count; leukopenia; loading drug dose; lung embolism; major clinical study; mucosa inflammation; multicenter study; multiple cycle treatment; nausea; neoadjuvant chemotherapy; neutropenia; neutrophil count; open study; osteoarthritis; pain; partial mastectomy; peripheral neuropathy; phase 3 clinical trial; platelet count; pneumonia; priority journal; quality of life; randomized controlled trial; rash; respiratory failure; sensory neuropathy; sepsis; side effect; sinus tachycardia; skin abscess; small intestine obstruction; stomatitis; thrombocytopenia; upper abdominal pain; upper respiratory tract infection; vaginitis; viral gastroenteritis; vomiting; wound infection; adjuvant chemotherapy; analogs and derivatives; Asia; breast tumor; Canada; cancer staging; clinical trial; comparative study; enzymology; Europe; female; middle aged; mortality; neoadjuvant therapy; pathology; time factor; treatment outcome; United States; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Breast Neoplasms; Canada; Carboplatin; Chemotherapy, Adjuvant; Europe; Female; Humans; Maytansine; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; United States
Publisher
Lancet Publishing Group
Type
journal article